We also reported that siRNA-mediated mutant KRAS knockdown and pharmacological inhibitors of MEK and ERK reduced PD-L1 expression in NSCLC cells with KRAS mutations and PD-L1 overexpression [97]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.